Due to extensive tumor vasculature, therapy for more advanced stages of ccRCC has focused on targeting the vascular endothelial growth factor (VEGF) signaling pathway with receptor tyrosine kinase inhibitors (TKIs) or monoclonal antibodies that block VEGF [3]. This evidence concerns the gene VEGFA and neoplasm.